



PharmaMar Appoints Pascal Besman as Chief Operating Officer of PharmaMar U.S.

- Newly-Created Executive Role to Support Company's Planned Expansion of U.S. Operations

Madrid and New York, November 15, 2016 – PharmaMar (MSE:PHM), a biotechnology company developing marine-derived oncology drugs, today announced that Pascal Besman has joined the company in the newly-created role of Chief Operating Officer, effective immediately. Mr. Besman will be based in New York and will oversee the implementation of PharmaMar's operational infrastructure in the United States. Mr. Besman joins PharmaMar from Maxim Group, a New York-based global investment bank, where he served as Head of Healthcare Equity Sales since 2014.

"With Yondelis on the market in the US and our key pipeline program PM1183 in several pivotal Phase 3 studies, now is the ideal time to welcome Pascal to our team as we further expand our presence in the U.S.," said José María Fernández Sousa-Faro, Ph.D., President, Chief Executive Officer and Chairman of the Board of PharmaMar. "As a global, revenue-generating oncology company, we look forward to leveraging Pascal's expertise in the biotechnology sector and U.S. capital markets as we continue to expand our efforts in the US."

"I have been impressed with PharmaMar's progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines," said Mr. Besman. "PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company's future success as we seek to continue building shareholder value."

In addition to Maxim Group, Mr. Besman served as a healthcare specialist and institutional equity salesperson at several investment banks, including JMP Securities, UBS, Bear Stearns, Lehman Brothers and Merrill Lynch. He authored a widely-read weekly biotech



overview newsletter for C-suite executives entitled *The Buzz*. Mr. Besman holds a B.Sc. from the London School of Economics.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com